BR112012018947B8 - anticorpo anti-caprin-1 monoclonal, composição farmacêutica, combinação farmacêutica e usos de uma composição farmacêutica, de um anticorpo e de uma combinação farmacêutica - Google Patents

anticorpo anti-caprin-1 monoclonal, composição farmacêutica, combinação farmacêutica e usos de uma composição farmacêutica, de um anticorpo e de uma combinação farmacêutica Download PDF

Info

Publication number
BR112012018947B8
BR112012018947B8 BR112012018947A BR112012018947A BR112012018947B8 BR 112012018947 B8 BR112012018947 B8 BR 112012018947B8 BR 112012018947 A BR112012018947 A BR 112012018947A BR 112012018947 A BR112012018947 A BR 112012018947A BR 112012018947 B8 BR112012018947 B8 BR 112012018947B8
Authority
BR
Brazil
Prior art keywords
antibody
pharmaceutical composition
pharmaceutical
caprin
cancer
Prior art date
Application number
BR112012018947A
Other languages
English (en)
Other versions
BR112012018947A8 (pt
BR112012018947B1 (pt
BR112012018947A2 (pt
Inventor
Okano Fumiyoshi
Kobayashi Shinichi
Saito Takanori
Ido Takayoshi
Narita Yoshinori
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of BR112012018947A2 publication Critical patent/BR112012018947A2/pt
Publication of BR112012018947A8 publication Critical patent/BR112012018947A8/pt
Publication of BR112012018947B1 publication Critical patent/BR112012018947B1/pt
Publication of BR112012018947B8 publication Critical patent/BR112012018947B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Abstract

anticorpo anti-caprin-1 monoclonal, composição farmacêutica, combinação farmacêutica e usos de uma composição farmacêutica, de um anticorpo e de uma combinação farmacêutica de acordo com a presente invenção, foi identificada uma proteína antígeno do câncer que é especificamente expressa sobre as superfícies de células cancerosas e, portanto, é fornecido o uso de um anticorpo direcionado contra a proteína antígeno do câncer como um agente para o tratamento e/ou prevenção de um câncer. especificamente, a presente invenção fornece uma composição farmacêutica para o tratamento e/ou prevenção de um câncer, que compreende um anticorpo ou fragmento do mesmo como um ingrediente ativo possuindo reatividade imunológica a um polipeptídeo parcial da caprin-1, que é representada por qualquer uma das sequências pares numeradas como seq id nos: 2 a 30, em que o polipeptídeo tem a sequência de aminoácidos representada pela seq id no: 37 ou uma sequência de aminoácidos possuindo 80% ou mais de identidade de sequência com a sequência de aminoácidos.
BR112012018947A 2010-02-04 2011-02-04 anticorpo anti-caprin-1 monoclonal, composição farmacêutica, combinação farmacêutica e usos de uma composição farmacêutica, de um anticorpo e de uma combinação farmacêutica BR112012018947B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010023451 2010-02-04
PCT/JP2011/052403 WO2011096528A1 (ja) 2010-02-04 2011-02-04 癌の治療及び／又は予防用医薬組成物

Publications (4)

Publication Number Publication Date
BR112012018947A2 BR112012018947A2 (pt) 2017-06-27
BR112012018947A8 BR112012018947A8 (pt) 2017-12-19
BR112012018947B1 BR112012018947B1 (pt) 2020-04-28
BR112012018947B8 true BR112012018947B8 (pt) 2020-06-02

Family

ID=44355522

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012018947A BR112012018947B8 (pt) 2010-02-04 2011-02-04 anticorpo anti-caprin-1 monoclonal, composição farmacêutica, combinação farmacêutica e usos de uma composição farmacêutica, de um anticorpo e de uma combinação farmacêutica

Country Status (15)

Country Link
US (1) US9115200B2 (pt)
EP (1) EP2532365B1 (pt)
JP (1) JP5742714B2 (pt)
KR (1) KR101842893B1 (pt)
CN (1) CN102821788B (pt)
BR (1) BR112012018947B8 (pt)
CA (1) CA2788715C (pt)
DK (1) DK2532365T3 (pt)
ES (1) ES2583627T3 (pt)
HU (1) HUE030103T2 (pt)
MX (1) MX340014B (pt)
PL (1) PL2532365T3 (pt)
PT (1) PT2532365T (pt)
RU (1) RU2607366C2 (pt)
WO (1) WO2011096528A1 (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2570731T3 (es) 2008-08-05 2016-05-20 Toray Industries Método de detección de cáncer
ES2502940T3 (es) 2008-08-05 2014-10-06 Toray Industries, Inc. Composición farmacéutica para el tratamiento y la prevención del cáncer
MX342291B (es) * 2010-02-04 2016-09-23 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
HUE030102T2 (en) 2010-02-04 2017-04-28 Toray Industries A pharmaceutical composition comprising anti-caprin-1 antibodies for the treatment and / or prevention of cancer
EP2532743B1 (en) 2010-02-04 2015-04-15 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
CN109925511B (zh) 2010-02-04 2024-03-19 东丽株式会社 用于癌的治疗和/或预防的药物
MX340017B (es) 2010-02-04 2016-06-22 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
CA2788715C (en) 2010-02-04 2021-06-08 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
BR112014002619A2 (pt) 2011-08-04 2018-10-09 Toray Industries, Inc composição farmacêutica e método de tratamento e/ou prevenção de câncer pancreático e combinação farmacêutica
DK2740798T3 (en) 2011-08-04 2017-03-06 Toray Industries Drug composition for cancer treatment and / or prevention
AU2012290957B2 (en) 2011-08-04 2017-04-20 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
DK2740794T3 (en) 2011-08-04 2018-06-14 Toray Industries PHARMACEUTICAL COMPOSITION FOR TREATMENT AND / OR CANCER PREVENTION
MX348579B (es) 2011-08-04 2017-06-20 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
JP6065591B2 (ja) 2011-08-04 2017-01-25 東レ株式会社 癌の治療及び／又は予防用医薬組成物
RU2624040C2 (ru) 2011-08-04 2017-06-30 Торэй Индастриз, Инк. Способ обнаружения рака поджелудочной железы
CA2864864C (en) 2012-02-21 2020-05-12 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
AU2013223147B2 (en) * 2012-02-21 2017-10-05 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
BR112014021099A2 (pt) * 2012-02-21 2020-12-01 Toray Industries, Inc anticorpo, composição farmacêutica, dna e método de tratamento e/ou prevenção de câncer e uso de um anticorpo
IN2014KN01715A (pt) 2012-02-21 2015-10-23 Toray Industries
JP6107655B2 (ja) 2012-03-30 2017-04-05 東レ株式会社 胆嚢癌の治療及び／又は予防用医薬組成物
PT2832365T (pt) * 2012-03-30 2018-01-24 Toray Industries Composição farmacêutica para o tratamento e/ou prevenção do cancro hepático
PT2876447T (pt) * 2012-07-19 2020-02-03 Toray Industries Método para deteção de cancro
ES2718348T3 (es) * 2012-07-19 2019-07-01 Toray Industries Método para detectar cáncer
AU2014303375B2 (en) * 2013-08-09 2019-07-04 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
MX2018011133A (es) * 2016-03-28 2019-01-14 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
CN115317603A (zh) 2016-07-07 2022-11-11 小利兰·斯坦福大学托管委员会 抗体佐剂缀合物
EP3533466A4 (en) * 2016-10-28 2020-06-10 Toray Industries, Inc. PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT AND / OR PREVENTION
US20210121562A1 (en) * 2018-03-30 2021-04-29 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
JP2022521723A (ja) 2019-02-15 2022-04-12 インテグラル・モレキュラー・インコーポレイテッド クローディン６抗体及びその使用
CN113661175A (zh) * 2019-02-15 2021-11-16 整体分子公司 包含共同轻链的抗体及其用途
WO2020190725A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
KR20220153615A (ko) 2020-03-12 2022-11-18 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
US20230139178A1 (en) 2020-03-12 2023-05-04 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
EP4119160A4 (en) 2020-03-12 2024-04-03 Toray Industries MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER
BR112022018166A2 (pt) 2020-03-12 2022-10-25 Toray Industries Medicamento para tratamento e/ou prevenção de câncer, agentes que aumentam a eficácia de droga de uma composição farmacêutica e método para tratar e/ou prevenir câncer
JPWO2021182573A1 (pt) 2020-03-12 2021-09-16
US11768197B1 (en) * 2021-06-19 2023-09-26 Eggschain, Inc. Rapid fertility and health indicator
BR112023026992A2 (pt) 2021-06-23 2024-03-12 Toray Industries Medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia do medicamento em uma composição farmacêutica e método para tratar e/ou prevenir o câncer
CN117545508A (zh) 2021-06-23 2024-02-09 东丽株式会社 用于癌的治疗和/或预防的药品
CN117677398A (zh) 2021-07-27 2024-03-08 东丽株式会社 用于癌的治疗和/或预防的药品
JPWO2023008459A1 (pt) 2021-07-27 2023-02-02
CA3227703A1 (en) 2021-07-27 2023-02-02 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
CA3230737A1 (en) 2021-09-03 2023-03-09 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
AU701342B2 (en) 1994-07-13 1999-01-28 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8
US5698396A (en) 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
FR2761994B1 (fr) 1997-04-11 1999-06-18 Centre Nat Rech Scient Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
SK14812000A3 (sk) 1998-04-03 2001-08-06 Chugai Seiyaku Kabushiki Kaisha Chimérny reťazec protilátky, chimérna protilátka, v oblasť, humanizovaný reťazec protilátky, humanizovaná protilátka, dna, expresný vektor, hostiteľ, spôsob prípravy a liečivo
US20030118599A1 (en) 1999-04-02 2003-06-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
RU2234942C2 (ru) 1998-07-14 2004-08-27 Корикса Корпорейшн Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид
KR20070112860A (ko) 1998-07-14 2007-11-27 코릭사 코포레이션 전립선 종양 단백질의 분리된 면역원성 부위 및 이를사용하여 전립선암을 진단하는 방법
US6969518B2 (en) 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
WO2000052204A2 (en) 1999-02-22 2000-09-08 Orntoft Torben F Gene expression in bladder tumors
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
JP2002540790A (ja) * 1999-04-02 2002-12-03 コリクサ コーポレイション 肺癌の治療および診断のための化合物ならびにその使用のための方法
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
EP1189641B1 (en) * 1999-06-25 2009-07-29 Genentech, Inc. HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES
EP1224285A4 (en) 1999-10-29 2004-12-08 Human Genome Sciences Inc 27 HUMAN SECRETED PROTEINS
US20020006404A1 (en) 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
JP2004526401A (ja) 2000-03-29 2004-09-02 コリクサ コーポレイション 肺癌の治療および診断のための組成物および方法
JP3523245B1 (ja) 2000-11-30 2004-04-26 メダレックス，インコーポレーテッド ヒト抗体作製用トランスジェニック染色体導入齧歯動物
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US20040029114A1 (en) 2001-01-24 2004-02-12 Eos Technology, Inc. Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
RU2306952C2 (ru) 2001-01-31 2007-09-27 Байоджен Айдек Инк. Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами
AU2002311787A1 (en) 2001-03-28 2002-10-15 Zycos Inc. Translational profiling
WO2002083070A2 (en) * 2001-04-10 2002-10-24 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
AU2002311909A1 (en) 2001-05-11 2002-11-25 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
CA2508763C (en) 2001-05-11 2012-01-24 Kirin Beer Kabushiki Kaisha Human antibody producing mouse and method for producing human antibody using the same
US20030190640A1 (en) 2001-05-31 2003-10-09 Mary Faris Genes expressed in prostate cancer
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
CA2476518A1 (en) 2002-02-22 2003-09-04 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20050003390A1 (en) * 2002-05-17 2005-01-06 Axenovich Sergey A. Targets for controlling cellular growth and for diagnostic methods
US20040126379A1 (en) 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
US20060121029A1 (en) 2002-08-30 2006-06-08 Hiroshi Shiku Method and composition for regulating the activity of regulatory t cells
WO2004047728A2 (en) 2002-11-26 2004-06-10 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2004076682A2 (en) 2003-02-26 2004-09-10 Surromed, Inc. Targets for controlling cellular growth and for diagnostic methods
EP1629119A2 (en) 2003-04-29 2006-03-01 Wyeth Methods for diagnosing aml and mds by differential gene expression
EP1639090A4 (en) 2003-06-09 2008-04-16 Univ Michigan COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING CANCER
US20070048738A1 (en) 2003-07-14 2007-03-01 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
US20050032113A1 (en) 2003-07-17 2005-02-10 Mitsubishi Pharma Corporation Membrane protein library for proteome analysis and method for preparing same
WO2005116076A2 (en) 2004-01-26 2005-12-08 Debiovision Inc. Neoplasm-specific polypeptides and their uses
ES2387809T3 (es) 2004-03-19 2012-10-02 Imclone Llc Anticuerpo frente al receptor del factor de crecimiento epidérmico humano
AU2005229457B2 (en) 2004-03-30 2010-11-25 Glaxo Group Limited Immunoglobulins
WO2005100998A2 (en) 2004-04-16 2005-10-27 Europroteome Ag Membrane markers for use in cancer diagnosis and therapy
DE102004026135A1 (de) 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
WO2006002378A2 (en) 2004-06-23 2006-01-05 Avalon Pharmaceuticals Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods
EP3698807A1 (en) 2005-01-21 2020-08-26 Genentech, Inc. Fixed dosing of her antibodies
CA2598217A1 (en) 2005-02-18 2006-08-24 Marsha A. Moses Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin
CN101189516A (zh) 2005-03-11 2008-05-28 赛弗吉生物系统公司 卵巢癌及子宫内膜癌的生物标记：抗菌蛋白（hepcidin）
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
US8014957B2 (en) 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
EP1991701A4 (en) 2006-02-14 2010-03-17 Dana Farber Cancer Inst Inc COMPOSITIONS, KITS, AND METHODS FOR IDENTIFYING, EVALUATING, PREVENTING, AND TREATING CANCER
US20100015724A1 (en) 2006-08-17 2010-01-21 Peter Hornbeck Lysine acetylation sites
US20080107668A1 (en) * 2006-08-30 2008-05-08 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US7615349B2 (en) 2006-09-07 2009-11-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanoma gene signature
WO2008059252A2 (en) 2006-11-15 2008-05-22 Oxford Biomedica (Uk) Limited Methods and composition fro t cell receptors which recognize 5t4 antigen
JP5663834B2 (ja) 2008-03-14 2015-02-04 東ソー株式会社 遺伝子組換え抗体の製造方法
JP2010023451A (ja) 2008-07-24 2010-02-04 Konica Minolta Business Technologies Inc 画像形成装置、画像形成方法および画像形成プログラム
US8454968B2 (en) 2008-08-05 2013-06-04 Toray Industries, Inc. Method for inducing immunity with a peptide fragment from human CAPRIN-1
ES2570731T3 (es) 2008-08-05 2016-05-20 Toray Industries Método de detección de cáncer
ES2502940T3 (es) * 2008-08-05 2014-10-06 Toray Industries, Inc. Composición farmacéutica para el tratamiento y la prevención del cáncer
JP5734978B2 (ja) 2009-08-19 2015-06-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｆｆｐｅ材料におけるインテグリン複合体検出のための抗体
WO2011035884A1 (en) 2009-09-22 2011-03-31 Volker Sandig Process for producing molecules containing specialized glycan structures
US9984787B2 (en) 2009-11-11 2018-05-29 Samsung Electronics Co., Ltd. Conductive paste and solar cell
HUE030102T2 (en) 2010-02-04 2017-04-28 Toray Industries A pharmaceutical composition comprising anti-caprin-1 antibodies for the treatment and / or prevention of cancer
CA2788715C (en) 2010-02-04 2021-06-08 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
MX340017B (es) 2010-02-04 2016-06-22 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
EP2532743B1 (en) 2010-02-04 2015-04-15 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
CN109925511B (zh) 2010-02-04 2024-03-19 东丽株式会社 用于癌的治疗和/或预防的药物
MX342291B (es) 2010-02-04 2016-09-23 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
RU2624040C2 (ru) 2011-08-04 2017-06-30 Торэй Индастриз, Инк. Способ обнаружения рака поджелудочной железы
BR112014002619A2 (pt) 2011-08-04 2018-10-09 Toray Industries, Inc composição farmacêutica e método de tratamento e/ou prevenção de câncer pancreático e combinação farmacêutica
AU2012290957B2 (en) 2011-08-04 2017-04-20 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
JP6107655B2 (ja) 2012-03-30 2017-04-05 東レ株式会社 胆嚢癌の治療及び／又は予防用医薬組成物
PT2832365T (pt) 2012-03-30 2018-01-24 Toray Industries Composição farmacêutica para o tratamento e/ou prevenção do cancro hepático

Also Published As

Publication number Publication date
CN102821788A (zh) 2012-12-12
JPWO2011096528A1 (ja) 2013-06-13
RU2012137498A (ru) 2014-03-10
EP2532365A1 (en) 2012-12-12
BR112012018947A8 (pt) 2017-12-19
DK2532365T3 (en) 2016-08-15
EP2532365A4 (en) 2013-12-04
JP5742714B2 (ja) 2015-07-01
CA2788715C (en) 2021-06-08
EP2532365B1 (en) 2016-05-04
WO2011096528A1 (ja) 2011-08-11
CN102821788B (zh) 2016-11-16
ES2583627T3 (es) 2016-09-21
PT2532365T (pt) 2016-07-28
BR112012018947B1 (pt) 2020-04-28
KR20120123500A (ko) 2012-11-08
PL2532365T3 (pl) 2016-12-30
BR112012018947A2 (pt) 2017-06-27
AU2011211693A1 (en) 2012-08-23
MX2012008999A (es) 2012-08-31
CA2788715A1 (en) 2011-08-11
US20120301476A1 (en) 2012-11-29
US9115200B2 (en) 2015-08-25
KR101842893B1 (ko) 2018-03-28
HUE030103T2 (en) 2017-04-28
RU2607366C2 (ru) 2017-01-10
MX340014B (es) 2016-06-22

Similar Documents

Publication Publication Date Title
BR112012018947B1 (pt) anticorpo anti-caprin-1 monoclonal, composição farmacêutica, combinação farmacêutica e usos de uma composição farmacêutica, de um anticorpo e de uma combinação farmacêutica
BR112012018951A8 (pt) anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
BR112014021101A2 (pt) Anticorpo, composição farmacêutica, droga de combinação, dna e método de tratamento e/ou prevenção de câncer, uso de um anticorpo
BR112012019098B8 (pt) anticorpo, composição farmacêutica, combinação farmacêutica e usos de um anticorpo, de uma composição farmacêutica e de uma combinação farmacêutica
MX357505B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX351682B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340015B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
CY1119435T1 (el) Σκευασμα για αντισωμα εναντι- αλφα4βητα7
BR112016001753A2 (pt) Anticorpo, anticorpo ou seu fragmento, composição de anticorpo, célula, composição farmacêutica, produto de droga de combinação e método de tratamento e/ou prevenção de câncer
MX363136B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX360211B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
DOP2015000240A (es) 3- pirimidin- 4- il- oxazolidin- 2- onas como inhibidores de idh mutante
MX2018011836A (es) Conjugados de anticuerpo farmaco anti-cd70.
BRPI0821110B8 (pt) anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo
BR112014021251A2 (pt) anticorpos humanos para toxinas de clostridium difficile
BR112015009037A2 (pt) composição farmacêutica para uso no tratamento de infarto do miocárdio e uso de um peptídeo de fragmento de hmgb1
BR112017019343A2 (pt) uso de composições contendo peptídeo inibidor de mk2 para tratamento de câncer de pulmão de células não pequenas com as mesmas
BR112014027991A2 (pt) agentes para neutralização de influenza
BR112015021483A2 (pt) arginina deiminase com reduzida reatividade cruzada para anticorpos adi-peg 20 para o tratamento do câncer
BR112013029417A2 (pt) composições de vacina de matriz proteica incluindo policátions
BR112015008745A2 (pt) método para tratamento de lesão ao cordão espinhal usando fragmento de hmgb1
BR112016016103A2 (pt) Composição de antígenos micobacterianos
BR112015022010A2 (pt) Uso de sdf-1 para mitigar a formação de cicatrizes
BR112019011350A2 (pt) terapia de combinação

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Notification to applicant to reply to the report for non-patentability or inadequacy of the application [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/02/2011, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant

Free format text: REF. RPI 2573 DE 28/04/2020 QUANTO AO ENDERECO.